Earnings Data
Report Date
Aug 10, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.04Last Year’s EPS
0.15Same Quarter Last Year
Moderate Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a mix of near-term headwinds tied to a deliberate strategic pivot (one-time restructuring charges, gross-margin pressure, GAAP loss and short-term volatility) alongside several strong growth signals: raised full-year revenue guide, rapid adoption of branded GLP-1 products (125k+ Wegovy shipments in six weeks and on track for >100k monthly subscribers), international revenue growth (~10x to $78M), positive operating cash flow ($89M) and deep investments in AI, labs and verticalized supply chain. Management expects accelerating EBITDA in H2 as monthly cohorts compound and efficiencies emerge. Given the substantial operational and commercial progress and the forward-looking guidance offsetting temporary accounting and margin noise, the positive operational momentum and upgraded outlook outweigh the short-term financial disruptions.Company Guidance
Revenue Growth and Raised Full-Year Guidance
Q1 revenue grew 4% year-over-year to $608 million. Management raised 2026 revenue guidance to $2.8 billion–$3.0 billion (a 19%–28% YoY increase) and expects Q2 revenue of $680 million–$700 million (25%–28% YoY).
Subscriber and Engagement Momentum
Subscribers increased 9% YoY to nearly 2.6 million. Early adoption in weight-loss branded products is driving engagement: on-track to add north of 100,000 new weight-loss subscribers per month, ~90% of these users downloaded the app and the average new branded-subscriber interacted with a provider 3 times in the first month.
Strong Early Adoption of Branded GLP-1s (Novo Partnership)
Within six weeks of offering direct access to Novo Nordisk GLP-1 products, the company fulfilled more than 125,000 Wegovy shipments. Customers responded well to the Wegovy pill (noted affordability, efficacy and safety).
Adjusted EBITDA and Back-Half Acceleration
Q1 adjusted EBITDA was $44 million (7% adjusted EBITDA margin). Company expects full-year adjusted EBITDA of $275 million–$350 million (implying ~11% margin at midpoint) and anticipates a meaningful step-up in adjusted EBITDA dollars in Q3 and Q4 as monthly cohorts compound and operating leverage improves.
Strong Cash Flow and Balance Sheet
Q1 cash flow from operations was $89 million and free cash flow was $53 million. Available cash and short-term investments were $751 million at quarter end, with $225 million remaining on the share repurchase program.
Rapid International Expansion
International revenue was $78 million in Q1, representing nearly a tenfold increase year-over-year driven by acquisitions (ZAVA, Livewell). Management expects the Eucalyptus acquisition to close in H2 2026 to further expand presence across Australia, U.K., Germany, Japan and Canada.
Technology, AI and Data Investments
Built an AI organization (~40 members) and launched provider AI copilots and a Labs AI agent; AI weight-loss companion coming. Platform rearchitecture (no-code commercial engine, configurable clinical workflows, improved mobile/messaging) intended to accelerate new category launches and drive efficiency and personalization.
Clinical and Product Proof Points
Testosterone specialty: 95% of customers relying on Hims for testosterone support saw an increase in testosterone levels within two months. Completed acquisition of YourBio to enable at-home blood collection and deeper biomarker insights.
DE:82W Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:82W Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 11, 2026 | €20.98 | €24.90 | +18.68% |
Feb 23, 2026 | €13.10 | €13.30 | +1.53% |
Nov 03, 2025 | €39.69 | €40.50 | +2.04% |
Aug 04, 2025 | €54.84 | €48.50 | -11.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Hims & Hers Health, Inc. (DE:82W) report earnings?
Hims & Hers Health, Inc. (DE:82W) is schdueled to report earning on Aug 10, 2026, TBA (Confirmed).
What is Hims & Hers Health, Inc. (DE:82W) earnings time?
Hims & Hers Health, Inc. (DE:82W) earnings time is at Aug 10, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Hims & Hers Health, Inc. stock?
The P/E ratio of Hims & Hers Health is N/A.
What is DE:82W EPS forecast?
DE:82W EPS forecast for the fiscal quarter 2026 (Q2) is -0.04.
